Lista de obras -

A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib

artículo científico publicado en 2014

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

artículo científico publicado en 2016

A review of the European LeukemiaNet recommendations for the management of CML.

artículo científico

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

artículo científico publicado en 2012

Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study

artículo científico publicado en 2015

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia

artículo científico publicado en 2017

Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells

artículo científico publicado en 2013

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

artículo científico publicado en 2017

DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia

artículo científico publicado en 2015

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

artículo científico publicado en 2010

Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

artículo científico

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells

artículo científico publicado en 2017

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

artículo científico publicado en 2018

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

artículo científico publicado en 2013

Essential Role of Lyn in Fibrosis

artículo científico publicado en 2016

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage

artículo científico publicado en 2017

First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies

artículo científico

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

article by Gabriele Gugliotta et al published 26 May 2011 in Blood

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

artículo científico publicado en 2018

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

artículo científico publicado en 2016

Imatinib in chronic myeloid leukemia elderly patients

artículo científico publicado en 2011

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

artículo científico publicado en 2013

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

artículo científico publicado en 2013

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

artículo científico publicado en 2016

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

artículo científico publicado en 2017

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

artículo científico publicado en 2012

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

artículo científico publicado en 2015

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

artículo científico publicado en 2011

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

artículo científico publicado en 2016

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

artículo científico

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

artículo científico publicado en 2009

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

artículo científico publicado en 2017

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

artículo científico publicado en 2009

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

article by Antonio Curti et al published November 2007 in British Journal of Haematology

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

artículo científico publicado en 2009

Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.

artículo científico publicado en 2011

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

artículo científico publicado en 2017

Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging

Response definitions and European Leukemianet Management recommendations

artículo científico publicado en 2009

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

artículo científico publicado en 2016

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

artículo científico publicado en 2011

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

artículo científico publicado en 2017

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

artículo científico publicado en 2010

Treatment recommendations for chronic myeloid leukemia

artículo científico publicado en 2014

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

artículo científico publicado en 2016

Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia

artículo científico publicado en 2017

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.

artículo científico publicado en 2011

Lista de obras de

A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib

A population-based study of chronic myeloid leukemia patients treated with imatinib in first line

A review of the European LeukemiaNet recommendations for the management of CML.

Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis.

Anagrelide treatment and cardiovascular monitoring in essential thrombocythemia. A prospective observational study

Chibby 1: a new component of β-catenin-signaling in chronic myeloid leukemia

Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells

Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy

DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia

Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'.

Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia

Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells

Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients.

Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia

Essential Role of Lyn in Fibrosis

FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage

First-line treatment of newly diagnosed elderly patients with chronic myeloid leukemia: current and emerging strategies

Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party

Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.

Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome

Imatinib in chronic myeloid leukemia elderly patients

Imatinib in very elderly patients with chronic myeloid leukemia in chronic phase: a retrospective study

Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors

In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants

Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia

Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib.

Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients

Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients

Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia

No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib

Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure

Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides

Philadelphia-positive patients who already harbor imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors.

Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.

Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series

Positive selection and transplantation of autologous highly purified CD133(+) stem cells in resistant/relapsed chronic lymphocytic leukemia patients results in rapid hematopoietic reconstitution without an adequate leukemic cell purging

Response definitions and European Leukemianet Management recommendations

Rotation of nilotinib and imatinib for first-line treatment of chronic phase chronic myeloid leukemia

Second-generation BCR-ABL inhibitors for frontline treatment of chronic myeloid leukemia in chronic phase

The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib

The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase

Treatment recommendations for chronic myeloid leukemia

Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom?

Valosin-Containing Protein/p97 as a Novel Therapeutic Target in Acute Lymphoblastic Leukemia

Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis.